Clinical Trials
3 trialsNCT04975555 2026-06-03
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
Phase 2 Completed
NCT06679829 2026-04-24
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03315026 2025-11-04
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting